Search
for
Sort by
Research 451–480 of 1000+
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Baricitinib for the Treatment of Alopecia Areata
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
- Ann Robinson’s research reviews —12 May 2022
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tofacitinib
- Emerging treatments in alopecia
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment
- Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib
- Review of modern methods of treating vitiligo
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- Deuruxolitinib for Alopecia Areata.
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances
- Tofacitinib in the Management of Alopecia Universalis
- Targeted immunotherapy for hair regrowth and regeneration
- Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US